Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
In: Blood, Jg. 140 (2022-11-15), Heft Supplement 1, S. 834-836
Online
academicJournal
Zugriff:
Titel: |
Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
|
---|---|
Autor/in / Beteiligte Person: | Huber, Henriette ; Tausch, Eugen ; Schneider, Christof ; Edenhofer, Simone ; Von Tresckow, Julia ; Robrecht, Sandra ; Giza, Adam ; Zhang, Can ; Furstenau, Moritz ; Dreger, Peter ; Ritgen, Matthias ; Illmer, Thomas ; Illert, Anna Lena ; Dürig, Jan ; Böttcher, Sebastian ; Niemann, Carsten Utoft ; Kneba, Michael ; Fink, Anna-Maria ; Fischer, Kirsten ; Döhner, Hartmut ; Hallek, Michael ; Eichhorst, Barbara ; Stilgenbauer, Stephan |
Link: | |
Zeitschrift: | Blood, Jg. 140 (2022-11-15), Heft Supplement 1, S. 834-836 |
Veröffentlichung: | 2022 |
Medientyp: | academicJournal |
ISSN: | 0006-4971 (electronic) |
DOI: | 10.1182/blood-2022-163245 |
Sonstiges: |
|